Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, reported its financial results, showing a net loss of $5.32 million for the period, compared to a net loss of $7.24 million in the prior period. The basic and diluted loss per share was $0.22, an improvement from a loss of $0.38 per share in the previous period. The weighted average number of shares outstanding was 23.81 million, up from 19.13 million previously. The company focuses on developing AllocetraTM, a universal cell therapy designed to reprogram macrophages to their homeostatic state, crucial for rebalancing the immune system and addressing life-threatening conditions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-082585), on August 29, 2025, and is solely responsible for the information contained therein.